By Fineline Cube 
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on August 14, 2025, that the official list price of its weight-loss treatment, Mounjaro (tirzepatide), in the UK will increase by up to 170%. The new price, which also applies to its namesake type 2 diabetes medication, will take effect in September. A one-month supply of the highest dose will rise from £122 to £330.
Impact on Patients
The price increase will primarily affect private-pay patients. The UK’s public healthcare system will not be impacted due to a separate agreement in place.
Policy Context
This move reflects the pharmaceutical industry’s response to policy changes in the U.S. market. U.S. President Donald Trump is advocating for lower domestic drug prices while encouraging price increases overseas. Eli Lilly CEO David Ricks highlighted that aligning U.S. and European drug prices remains a long-term goal, though European governments have been reluctant to pay more for drugs.
Company Strategy
Eli Lilly is collaborating with private UK healthcare providers, including online pharmacies, which can set their own prices. This ensures continued access to Mounjaro for patients who rely on private healthcare services.